Hearing aid maker Sonitus lands $13.5M
Sonitus Medical, a company that makes a hearing device to treat single-sided deafness, just brought in $13.5 million in second-round funding to commercialize its flagship product, reports VentureWire. Based in San Mateo, Calif., it still needs to push the device through one more clinical trial… Continue Reading
Intradigm closes $21.4M for cancer therapeutics
Biotech firm Intradigm has tacked an additional $2.9 million onto its second round of funding, bringing its total to $21.4 million. The new money will be used to advance its RNA interference-based line of therapeutics used to treat cancer.
The Palo Alto, Calif.-based company says it… Continue Reading
Phenomix cancels IPO, finds new lab partner
Biopharmaceuticals company Phenomix withdrew its filing to go public yesterday and right away announced a $340-million collaboration deal with Forest Laboratories. The IPO, intended to raise $86.3 million, had been pending since January.
Forest will aid the San Diego-based firm in the development of its diabetes… Continue Reading
Intradigm lands $18.5M to advance oncology treatment
Intradigm, a biotech company that develops RNA interference treatments for cancer, announced today that it took $18.5 million in a second round of financing that included new investors Lilly Ventures, Roche Venture Fund, MP Healthcare Venture Management, and existing investors Alta Partners, Frazier Healthcare Ventures,… Continue Reading
Life-science briefing: Tuesday, March 18, 2008
TODAY’S HEADLINES:
Luminous Medical raises $24M for automated glucose monitoring (release)
Alimera Sciences gets $30M for eye-disease drug (release)
Vaccine maker LigoCyte draws $28M (release)
Heartbeat tracker CardioNet trims IPO, aims for listing today (IPOhome)
Axial Biotech takes in $6M for spinal diagnostics (release)
Insulin bioengineer enGene receives $6.4M (release)
GlucoLight raises… Continue Reading
Life sciences briefing: Monday, Sept. 24, 2007
Featured companies: Adnexus Therapeutics, Bristol-Myers Squibb, Cellerix, Elixir Therapeutics, GenomeQuest, Intronn, JapanBridge, JenaValve, VirXsys, Ysios Capital
[NOTE: This item is a catchup daily briefing originally posted on 9/27/07. I've edited the item's timestamp to preserve the chronological order of the briefings. --D.P.H.]
Adnexus Thera cancels IPO, sells… Continue Reading
Funding roundup: Announcements that got away
Although I try to stay on top of events in the life sciences, announcements do sometimes manage to slip through the cracks. Some days, in fact, I end up triaging. Because the roots of this site — not to mention many of its readers —… Continue Reading
Ablation Frontiers raises $22M for treating arrythmia
Ablation Frontiers, a Carlsbad, Calif., developer of devices for treating irregular heartbeats known as cardiac arrythmias, raised $21.8 million in a third funding round. The Novartis Venture Fund led the round, joined by Affinity Ventures, Hexagon Investments, Trellis Health Ventures, Versant Ventures, Aberdare Ventures, and… Continue Reading
Aileron Therapeutics pulls in $7M for peptide therapies
Aileron Therapeutics, a Cambridge, Mass., developer of peptide-based drugs for cancer, raised $7 million in a second funding round. The company is at work on a new class of “stapled” peptides, or protein fragments, that it says can penetrate cell walls.
Proteins and peptides make… Continue Reading
Antibiotic maker BioRelix gets $26M
BioRelix, a New Haven, Conn., developer of new antibiotics, raised $25.75 million in a first funding round, VentureWire reports (subscription required). The round included New Leaf Venture Partners, Aisling Capital, CHL Medical Partners, Novartis Venture Fund, Elm Street Ventures and Alexandria Real Estate Equities.
BioRelix is… Continue Reading
ProCertus pulls in $2.3M for prevention of chemo, radiation side effects
ProCertus BioPharm, a Madison, Wis., company developing drugs to minimize the side effects of radiation and chemotherapy, raised $2.3 million in a first round of financing. The company will use the money to begin human tests of products such as DermX, which is supposed to… Continue Reading